On 2 November 2026, Fresenius announced that it has entered an exclusive development agreement with WuXi Biologics, a large-scale biologics developer and manufacturer of monoclonal and bispecific antibodies and antibody-drug conjugates. According to Fresenius, this is the largest development agreement announced in the biosimilars industry to date.
The agreement provides Fresenius with exclusive access to up to 37 identified biosimilar candidates over the next decade. If Fresenius exercises all of its options, its portfolio of marketed and pipeline molecules would grow from 29 to as many as 66.
The products developed under the agreement are expected to span 13 therapeutic areas, including neurology, nephrology, cardiopulmonary, oncology, immunology, and gastroenterology, and will include monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Initial development is expected to focus on polatuzumab vedotin, biosimilar to Genentech’s Polivy®, an antibody-drug conjugate for the treatment of diffuse large B-cell lymphoma, and teprotumumab, biosimilar to Amgen’s Tepezza®, a monoclonal antibody for the treatment of Thyroid Eye Disease.
Under the terms of the agreement, WuXi will be paid on a fee-for-service basis for each candidate Fresenius selects for development. Fresenius retains exclusive global commercialisation rights, including marketing authorisations, and the full economics of any commercialised products.
The agreement builds on Fresenius’ full acquisition of mAbxience, completion of which was announced on 1 October 2026.